Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe (REFRAME-MP)

November 12, 2026 updated by: University Medical Center Groningen

Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe (REFRAME-MP)

Machine perfusion (MP) has become routine clinical practice in liver transplantation. However, as the field has matured, direct randomized comparisons between distinct MP modalities have become increasingly impractical, given that donor and graft characteristics often predetermine the optimal preservation strategy. Consequently, many studies continue to reference historical benchmark cohorts from the pre-perfusion era, or use risk scores developed before routine utilization of MP. These cohorts, while once valuable, fail to account for the paradigm shift that MP has introduced. Likewise, commonly used donor- and recipient-based risk scores were developed prior to the adoption of MP. While these scores aim to assess survival or morbidity after transplantation, none of them guide decisions about MP use or the most suitable perfusion protocol. As MP technologies continue to evolve there is a critical need for an updated reference framework that accurately reflects current clinical practice and captures the best achievable outcomes across all MP modalities.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The aim of this study is to establish a reference framework for liver transplantation outcomes in the era of routine clinical machine perfusion. In addition, based on the collected real-world observational data, a target trial emulation approach will be applied.

Study Type

Observational

Enrollment (Estimated)

10000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Innsbruck, Austria
        • Recruiting
        • Medical University of Innsbruck
        • Contact:
        • Principal Investigator:
          • Stefan Schneeberger, MD, PhD
      • Vienna, Austria
        • Not yet recruiting
        • Medical University of Vienna
        • Contact:
        • Principal Investigator:
          • Deniz Uluk, MD
      • Brussels, Belgium
        • Not yet recruiting
        • Cliniques universitaires Saint-Luc
        • Contact:
        • Principal Investigator:
          • Eliano Bonaccorsi-Riani, MD, PhD
      • Ghent, Belgium
        • Not yet recruiting
        • UZ Ghent
        • Contact:
        • Principal Investigator:
          • Hasan Eker, MD, PhD
      • Leuven, Belgium
        • Not yet recruiting
        • University Hospitals Leuven
        • Contact:
        • Principal Investigator:
          • Diethard Monbaliu, MD, PhD
      • Prague, Czechia
        • Not yet recruiting
        • Institute of Clinical and Experimental Medicine
        • Contact:
        • Principal Investigator:
          • Jiri Froněk, MD, PhD
      • Clermont-Ferrand, France
        • Not yet recruiting
        • Clermont-Ferrand University Hospital
        • Contact:
        • Principal Investigator:
          • Johan Gagnière, MD, PhD
      • Clichy, France
        • Not yet recruiting
        • Beaujon Hospital
        • Contact:
        • Principal Investigator:
          • Mickaël Lesurtel, MD, PhD
      • Lyon, France
        • Not yet recruiting
        • Hôpital de la Croix-Rousse
        • Contact:
        • Principal Investigator:
          • Xavier Muller, MD, PhD
      • Nice, France
        • Not yet recruiting
        • Nice University Hospital
        • Contact:
        • Principal Investigator:
          • Michel Rayar, MD, PhD
      • Strasbourg, France
        • Not yet recruiting
        • Hautepierre Hospital
        • Contact:
        • Principal Investigator:
          • Pietro Francesco Addeo, MD, PhD
      • Villejuif, France
        • Not yet recruiting
        • Hôpital Paul-Brousse Ap-Hp
        • Contact:
        • Principal Investigator:
          • Marc-Antoine Allard, MD, PhD
      • Aachen, Germany
        • Not yet recruiting
        • Aachen University Hospital
        • Contact:
        • Principal Investigator:
          • Florian Vondran, MD, PhD
      • Berlin, Germany
        • Not yet recruiting
        • Charité - Universitätsmedizin Berlin
        • Contact:
        • Principal Investigator:
          • Nathanael Raschzok, MD, PhD
      • Bonn, Germany
        • Not yet recruiting
        • University Hospital Bonn
        • Contact:
        • Principal Investigator:
          • Christiane Pillny, MD
        • Principal Investigator:
          • Steffen Manekeller, MD, PhD
      • Essen, Germany
        • Recruiting
        • University Hospital Essen
        • Principal Investigator:
          • Ulf Neumann, MD, PhD
        • Contact:
        • Principal Investigator:
          • Zoltan Czigany, MD, PhD
      • Hanover, Germany
        • Not yet recruiting
        • Hannover Medical School
        • Contact:
        • Principal Investigator:
          • Moritz Schmelzle, MD, PhD
      • Heidelberg, Germany
        • Not yet recruiting
        • University Hospital Heidelberg
        • Contact:
        • Principal Investigator:
          • Peri Husen, MD, PhD
        • Principal Investigator:
          • Christoph Mickalski, MD, PhD
      • Magdeburg, Germany
        • Not yet recruiting
        • University Hospital Magdeburg
        • Contact:
        • Principal Investigator:
          • Roland Croner, MD, PhD
      • München, Germany
        • Not yet recruiting
        • Ludwig Maximilian University of Munich
        • Contact:
        • Principal Investigator:
          • Dionysios Koliogiannis, MD
      • Münster, Germany
        • Not yet recruiting
        • University Hospital Muenster
        • Contact:
        • Principal Investigator:
          • Philipp Houben, MD, PhD
        • Principal Investigator:
          • Andreas Pascher, MD, PhD
      • Tübingen, Germany
        • Not yet recruiting
        • Tübingen University Hospital
        • Contact:
        • Principal Investigator:
          • Silvio Nadalin, MD, PhD
      • Bari, Italy
        • Not yet recruiting
        • A.O.U Consorziale Policlinico di Bari
        • Contact:
        • Principal Investigator:
          • Francesco Tandoi, MD, PhD
      • Bergamo, Italy
        • Not yet recruiting
        • Ospedale Papa Giovanni XXIII
        • Contact:
        • Principal Investigator:
          • Stefania Camagni, MD
        • Principal Investigator:
          • Domenico Pinelli, MD, PhD
      • Bologna, Italy
        • Not yet recruiting
        • Policlinico S.Orsola-Malpighi
        • Principal Investigator:
          • Matteo Cescon, MD, PhD
        • Contact:
      • Milan, Italy
        • Not yet recruiting
        • ASST Niguarda Great Metropolitan Hospital
        • Contact:
        • Principal Investigator:
          • Stefano Di Sandro, MD, PhD
      • Milan, Italy
        • Not yet recruiting
        • Istituto Nazionale dei Tumori
        • Principal Investigator:
          • Vincenzo Mazzaferro, MD, PhD
        • Contact:
        • Sub-Investigator:
          • Marco Angelo Bongini, MD, MSc
      • Milan, Italy
        • Not yet recruiting
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
        • Contact:
        • Principal Investigator:
          • Daniele Dondossola, MD, PhD
      • Pisa, Italy
        • Not yet recruiting
        • A.O.U. Pisana - Ospedale Cisanello
        • Contact:
        • Principal Investigator:
          • Davide Ghinolfi, MD, PhD
      • Roma, Italy
        • Not yet recruiting
        • Agostino Gemelli University Policlinic
        • Contact:
        • Principal Investigator:
          • Marco Maria Pascale, MD
        • Principal Investigator:
          • Ugo Boggi, MD, PhD
      • Roma, Italy
        • Not yet recruiting
        • Clinica ospedaliero-universitaria Policlinico Umberto I
        • Contact:
        • Principal Investigator:
          • Fabio Melandro, MD, PhD
        • Principal Investigator:
          • Massimo Rossi, MD, PhD
      • Torino, Italy
        • Recruiting
        • A.O.U. Città della Salute e della Scienza
        • Contact:
        • Principal Investigator:
          • Damiano Patrono, MD, PhD
      • Verona, Italy
        • Not yet recruiting
        • A.O.U. Integrata Verona
        • Contact:
        • Principal Investigator:
          • Amedeo Carraro, MD, PhD
      • Groningen, Netherlands
        • Recruiting
        • University Medical Center Groningen
        • Principal Investigator:
          • Vincent E de Meijer, MD, PhD
        • Contact:
      • Leiden, Netherlands
        • Not yet recruiting
        • Leiden University Medical Center
        • Contact:
        • Principal Investigator:
          • Ian Alwayn, MD, PhD
      • Bucharest, Romania
        • Not yet recruiting
        • Institutul Clinic Fundeni
        • Contact:
        • Principal Investigator:
          • Florin Botea, MD, PhD
      • Barakaldo, Spain
        • Not yet recruiting
        • Cruces University Hospital
        • Contact:
        • Principal Investigator:
          • Mikel Gastaca, MD, PhD
      • Barcelona, Spain
        • Not yet recruiting
        • Hospital Clínic de Barcelona
        • Contact:
        • Principal Investigator:
          • Yiliam Fundora Suárez, MD, PhD
      • Granada, Spain
        • Not yet recruiting
        • Hospital Universitario Virgen de las Nieves
        • Contact:
          • Alejandro J. Pérez Alonso, MD, PhD
          • Phone Number: +34958020000
          • Email: alpeal@ugr.es
        • Principal Investigator:
          • Alejandro J. Pérez Alonso, MD, PhD
      • Madrid, Spain
        • Not yet recruiting
        • Hospital General Universitario Gregorio Marañón
        • Contact:
          • María Magdalena Salcedo Plaza, MD, PhD
          • Phone Number: +34915868000
          • Email: msalce01@ucm.es
        • Principal Investigator:
          • María Magdalena Salcedo Plaza, MD, PhD
      • Seville, Spain
        • Not yet recruiting
        • Hospital Universitario Virgen del Rocío
        • Contact:
        • Principal Investigator:
          • Miguel Angel Gómez Bravo, MD, PhD
      • Valladolid, Spain
        • Not yet recruiting
        • Río Hortega University Hospital
        • Contact:
        • Principal Investigator:
          • Andrea González De Godos, MD
      • Stockholm, Sweden
        • Not yet recruiting
        • Karolinska Institutet
        • Contact:
        • Principal Investigator:
          • Gabriel Oniscu, MD, PhD
      • Bern, Switzerland
        • Not yet recruiting
        • Bern University Hospital
        • Principal Investigator:
          • Philipp Dutkowski, MD, PhD
        • Contact:
      • Geneva, Switzerland
        • Not yet recruiting
        • Hôpitaux Universitaires de Genève
        • Contact:
        • Principal Investigator:
          • Philippe Compagnon, MD, PhD
      • Leeds, United Kingdom
        • Not yet recruiting
        • Leeds Teaching Hospitals NHS Trust
        • Contact:
        • Principal Investigator:
          • Dhakshina Vijayanand, MD, PhD
      • London, United Kingdom
        • Not yet recruiting
        • Royal Free London NHS Foundation Trust
        • Contact:
        • Principal Investigator:
          • David Nasralla, MD, PhD
      • London, United Kingdom
        • Not yet recruiting
        • King's College Hospital NHS Foundation Trust
        • Contact:
        • Principal Investigator:
          • Miriam Cortes Cerisuelo, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer between 01.01.2021 and 31.12.2025 for patients >18 years at the time of liver transplantation.

Description

Inclusion Criteria:

  • All postmortal livers accepted (transplanted and not-transplanted after machine perfusion) upon organ offer for patients >18 years at the time of liver transplantation.

  • All donor types (DBD, DCD)

  • Preservation either with static cold storage alone or combined with machine perfusion (MP).

  • Donor livers underwent MP as part of routine clinical practice and the choice of perfusion protocol was made according to institutional standard practice.

  • Eligible MP protocols are:

    1. end-ischemic single- or dual hypothermic oxygenated MP [e(D)HOPE],
    2. end-ischemic (back-to-base) normothermic MP [eNMP],
    3. continuous (device-to-donor) normothermic MP [cNMP],
    4. e(D)HOPE followed by controlled oxygenated rewarming and normothermic MP [e(D)HOPE-COR-NMP)],
    5. e(D)HOPE followed by normothermic MP [e(D)HOPE-NMP], or
    6. Normothermic regional perfusion followed by SCS or an ex situ MP protocol.
  • A minimum follow-up of 12 months after liver transplantation is required.

Exclusion Criteria:

  • Livers that were allocated to a MP protocol as part of a prospective randomized or interventional clinical trial comparing different preservation techniques or any other invention.
  • Living donor liver transplantation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: RETROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Death-censored graft survival
Time Frame: Actuarial survival 1-5 year post-transplantation

Defined as the time from liver transplantation until re-transplantation or death due to graft failure (analyzed using time-to-event methods).

Actuarial survival 1-5 year post-transplantation
Overall patient survival
Time Frame: Actuarial survival 1-5 year post-transplantation

Defined as time from liver transplantation until re-transplantation or all-cause death (analyzed using time-to-event methods).

Actuarial survival 1-5 year post-transplantation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of acute rejection
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
within 1 year post-transplantation, up to 5 years post-transplantation
Incidence of chronic rejection
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation
within 1 year post-transplantation, up to 5 years post-transplantation
Overall graft survival
Time Frame: Actuarial survival 1-5 year post-transplantation

Defined as time from liver transplantation until re-transplantation or all-cause death (analyzed using time-to-event methods)

Actuarial survival 1-5 year post-transplantation
Incidence of major liver-related complications
Time Frame: within the transplant-related admission, and 1 year post-transplantation

Incidence of at least one biliary or vascular complication graded as Clavien-Dindo IIIb or higher, following the grading recommendations published: de Goeij FHC, Wehrle CJ, Abbassi F, et al. Mastering the narrative: Precision reporting of risk and outcomes in liver transplantation. J Hepatol. 2025;82(4):729-743. doi:10.1016/j.jhep.2024.11.013. Additionally, scoring accoring the Comprehensive Complication Index.

within the transplant-related admission, and 1 year post-transplantation
Incidence of graft loss due to complications
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation

Graft loss as a result of complications assessed separately for biliary complications, vascular complications, and rejection.

within 1 year post-transplantation, up to 5 years post-transplantation
Total number of clinically significant biliary complications
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation

Total number of any biliary complications requiring interventions (Clavien-Dindo grade IIIa or higher).

within 1 year post-transplantation, up to 5 years post-transplantation
Incidence of biliary complications
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation

Biliary complications include:

  • Post-transplant cholangiopathy
  • Anastomotic strictures
  • Biliary leakage
within 1 year post-transplantation, up to 5 years post-transplantation
Incidence of vascular complications
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation

Vascular complications include:

  • Hepatic artery thrombosis
  • Portal vein thrombosis
  • Venous outflow tract obstruction
within 1 year post-transplantation, up to 5 years post-transplantation
Incidence of re-transplantation
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation

Re-transplantation for any cause.

within 1 year post-transplantation, up to 5 years post-transplantation
Incidence of recurrence of primary disease
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation

Histologically or radiologically confirmed recurrence, including recurrence of malignancies

within 1 year post-transplantation, up to 5 years post-transplantation
Incidence of kidney injury
Time Frame: within 1 year post-transplantation, up to 5 years post-transplantation

Kidney injury includes:

  • Acute kidney injury
  • New-onset chronic kidney disease
within 1 year post-transplantation, up to 5 years post-transplantation
Incidence of primary non-function
Time Frame: up to 1 week post-transplantation

Liver graft failure within the first 7 days of transplantation with patent liver vessels leading to re-transplantation or patient death

up to 1 week post-transplantation
Patient-centered outcomes (measure of recovery and healthcare utilization)
Time Frame: within 1 year post-transplantation

Length of intensive care unit stay and length of initial hospital stay (starting at day of transplantation until day of discharge, measured in days)

within 1 year post-transplantation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Vincent E de Meijer, MD, PhD, University Medical Center Groningen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 21, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2030

Study Registration Dates

First Submitted

April 21, 2026

First Submitted That Met QC Criteria

May 11, 2026

First Posted (Actual)

May 14, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • UMCG_REFRAME-MP
  • METc 2026/180 (Registry Identifier: UMCG METc number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.